Prestige Consumer Healthcare
PBHNYSEUSD
- Source valuation snapshot. Not a live recalculation.
- Latest filed annual earnings; price snapshot date unavailable. Not forward P/E.
- Diluted earnings per share from the latest filed annual.
- $44.97 Prior regular-session close from the quote source.
- $43.69–$44.78 Regular-session low and high so far today.
- 386.2K Regular-session shares traded · Nov 11, 4:00 PM ET.
- Feb 4 projected Projected for 2027-02-04 from the company’s own results filings (SEC 8-K Item 2.02). The company has not confirmed the date.
- $41.77–$71.07 52-week trading low and high returned by the quote source.
Understand the Business
Why the Stock Moved
Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.
The core investment thesis
Own PBH if brand equity and retailer shelf space hold, but FY2026 revenue weakness makes organic durability the key test.
PBH price history
Loading recent earnings…
Investment thesis
What must happen next
PBH’s niche OTC brands will continue to earn branded economics because consumer familiarity and retailer shelf presence prevent rapid substitution by private label or larger competitors.HoldingMateriality: High
FY2026 annual GAAP gross_profit was $595.6 million on $1.089 billion of revenue, implying a gross margin of about 54.7%. If this holds, PBH can remain a high-margin cash generator even with modest category growth; if it breaks, the business becomes a lower-margin commodity OTC portfolio.
Watch: Walmart, CVS, Walgreens, or other major retailers expand store-brand/private-label shelf space in PBH’s core OTC categories.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
FY2026 annual GAAP gross_profit was $595.6 million on $1.089 billion of revenue, implying a gross margin of about 54.7%.
Open source ↗The portfolio model will keep converting mature OTC sales into cash because PBH can harvest established brands without a manufacturing- or R&D-heavy cost structure.StrengtheningMateriality: High
FY2026 annual GAAP operating_cash_flow was $257.6 million, up from $251.5 million in FY2025. Cash conversion is what funds debt reduction, brand support, and future acquisitions; if it weakens, the investment case loses its compounding engine.
Watch: Contract manufacturers or suppliers create service-level failures that require costly inventory buffers or emergency sourcing.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
FY2026 annual GAAP operating_cash_flow was $257.6 million, up from $251.5 million in FY2025.
Open source ↗PBH’s acquisition-led brand-ownership strategy will create value only if cash flow continues to reduce balance-sheet risk before the company takes on the next major deal.HoldingMateriality: Medium
Total liabilities were $1.607 billion at FY2026 year-end, down from $1.907 billion at FY2023 year-end. Lower leverage increases strategic flexibility; renewed debt-funded acquisitions before organic stability returns would raise downside risk.
Watch: Management announces a large debt-funded acquisition before stabilizing organic demand.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Total liabilities were $1.607 billion at FY2026 year-end, down from $1.907 billion at FY2023 year-end.
Open source ↗PBH needs consumer pull-through and retailer support for its mature OTC brands to recover from FY2026 weakness without relying mainly on discounting or acquisitions.WeakeningMateriality: Medium
Annual GAAP revenue was relatively stable from FY2023 through FY2025: $1.128 billion, $1.125 billion, and $1.138 billion. If organic demand recovers, the business can compound from its existing portfolio; if not, cash flow may be consumed defending brands or buying growth.
Watch: Private-label share gains persist in PBH’s core OTC categories even after pricing normalizes.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Annual GAAP revenue was relatively stable from FY2023 through FY2025: $1.128 billion, $1.125 billion, and $1.138 billion.
Open source ↗PBH can preserve high operating profitability if the cost to defend legacy brands does not structurally reset higher.HoldingMateriality: Medium
FY2026 annual GAAP operating_income was $309.4 million, implying an operating margin of about 28.4%. Operating income is the bridge from brand economics to shareholder earnings; if defense costs rise, revenue stabilization may not translate into value.
Watch: Retailers demand higher trade spending or slotting support to maintain PBH shelf positions.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
FY2026 annual GAAP operating_income was $309.4 million, implying an operating margin of about 28.4%.
Open source ↗
Full investment case & evidence
Loading the original research archive…
Original research
PBH’s niche OTC brands will continue to earn branded economics because consumer familiarity and retailer shelf presence prevent rapid substitution by private label or larger competitors. If this holds, PBH can remain a high-margin cash generator even with modest category growth; if it breaks, the business becomes a lower-margin commodity OTC portfolio.
The portfolio model will keep converting mature OTC sales into cash because PBH can harvest established brands without a manufacturing- or R&D-heavy cost structure. Cash conversion is what funds debt reduction, brand support, and future acquisitions; if it weakens, the investment case loses its compounding engine.
PBH’s acquisition-led brand-ownership strategy will create value only if cash flow continues to reduce balance-sheet risk before the company takes on the next major deal. Lower leverage increases strategic flexibility; renewed debt-funded acquisitions before organic stability returns would raise downside risk.
PBH needs consumer pull-through and retailer support for its mature OTC brands to recover from FY2026 weakness without relying mainly on discounting or acquisitions. If organic demand recovers, the business can compound from its existing portfolio; if not, cash flow may be consumed defending brands or buying growth.
PBH can preserve high operating profitability if the cost to defend legacy brands does not structurally reset higher. Operating income is the bridge from brand economics to shareholder earnings; if defense costs rise, revenue stabilization may not translate into value.
All standing thesis claims
Original report summary
brand equity and retailer shelf space hold, but FY2026 revenue weakness makes organic durability the key test.
Bull case and bear case
Bull case and bear case for Prestige Consumer Healthcare
Where the evidence on Prestige Consumer Healthcare disagrees: Mixed on the latest evidence (Nov 10, 2026). Of its 5 thesis points, 1 strengthening, 3 holding and 1 weakening.
Bull case: what the evidence supports
PBH’s niche OTC brands will continue to earn branded economics because consumer familiarity and retailer shelf presence prevent rapid substitution by private label or larger competitors.
The portfolio model will keep converting mature OTC sales into cash because PBH can harvest established brands without a manufacturing- or R&D-heavy cost structure.
PBH’s acquisition-led brand-ownership strategy will create value only if cash flow continues to reduce balance-sheet risk before the company takes on the next major deal.
PBH can preserve high operating profitability if the cost to defend legacy brands does not structurally reset higher.
Bear case: what the evidence questions
PBH needs consumer pull-through and retailer support for its mature OTC brands to recover from FY2026 weakness without relying mainly on discounting or acquisitions.
Thesis-Break Engine
Thesis-break watch · Prestige Consumer Healthcare
No break has crossed Prestige Consumer Healthcare’s thesis. Its break conditions are checked against every new filing as it lands.
MARKET + FINANCIAL SNAPSHOT
The numbers behind the thesis
What Changed
No assessed change was returned in this research window. That can reflect a quiet period or a coverage limit.
Risks / falsifiers
What could break the thesis
- Walmart, CVS, Walgreens, or other major retailers expand store-brand/private-label shelf space in PBH’s core OTC categories.
- Contract manufacturers or suppliers create service-level failures that require costly inventory buffers or emergency sourcing.
- Management announces a large debt-funded acquisition before stabilizing organic demand.
- Private-label share gains persist in PBH’s core OTC categories even after pricing normalizes.
- Retailers demand higher trade spending or slotting support to maintain PBH shelf positions.
PBH news
Loading headlines…
Financial statements
PBH income statement
Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.
PBH: quick answers
- When does Prestige Consumer Healthcare (PBH) report earnings next?
- Prestige Consumer Healthcare's next results are projected for February 4, 2027, from the dates of its own results filings with the SEC. The company has not confirmed the date. It last reported on November 5, 2026. Earnings calendar
- What is PBH's short interest?
- As of October 30, 2026, 4.2M PBH shares were sold short, 8.95% of its shares outstanding, up 7.1% from the count before. At the stock's average daily volume that is 8.1 days to cover. FINRA publishes the count twice a month. PBH short interest history
- Have members of Congress traded PBH?
- 5 trades in PBH have been disclosed under the STOCK Act by members of Congress, the President or senior officials, none in reports made public in the last 90 days. Every disclosed PBH trade
- Which well-known investors own PBH?
- 2 of the 37 well-known funds tracked here reported PBH shares in their latest 13F filings. By share of the fund's portfolio: Maverick Capital, 0.0%; Bridgewater Associates (Ray Dalio), 0.0%. Fund portfolios
PBH in well-known investors’ portfolios
2 of 37 funds reported PBH shares in their latest 13F filing. A 13F shows quarter-end positions and arrives up to 45 days later.
| Fund | Of its portfolio | Value | Change | Quarter |
|---|---|---|---|---|
| Maverick Capital | 0.02% | $2.4M | New | Q2 2026 |
| Ray DalioBridgewater Associates | 0.01% | $2.2M | New | Q2 2026 |